The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR

School of Clinical Medical Sciences, University of Newcastle upon Tyne, UK. s.g.ashwell@ncl.ac.uk

OBJECTIVE: Lanreotide Autogel is a sustained-release aqueous gel formulation supplied in a prefilled syringe, with injection volume <0.5 ml. The aim of this study was to establish the efficacy and safety of Autogel in patients with acromegaly previously treated with octreotide LAR. DESIGN: A 28-week, open, multicentre study. PATIENTS: Twelve patients with acromegaly, treated with 20 mg octreotide LAR for >4 months, with serum GH levels <10.0 mU/l. METHODS: Autogel (90 mg) was given every 28 days during weeks 0-12. At week 16 the dose was titrated based on GH levels at weeks 8 and 12. If GH levels were <2.0, 2.0-5.0, or >5.0 mU/l, Autogel was reduced to 60 mg, maintained at 90 mg, or increased to 120 mg respectively, for the next three injections. GH and IGF-I levels were reassessed at weeks 24 and 28. RESULTS: Ten patients completed the study. Five remained on 90 mg Autogel throughout the study; in two patients the dose was reduced to 60 mg from week 16; in three patients it was increased to 120 mg. Mean GH levels were: baseline, 3.0+/-1.7 mU/l; week 12, 3.5+/-1.8 mU/l; week 28, 3.3+/-1.6 mU/l (NS). Mean IGF-I levels were: baseline, 212+/-70 microg/l; week 12, 185+/-91 microg/l; week 28: 154+/-61 microg/l (P=0.027). Six patients at baseline and eight at week 28 had normalised GH and IGF-I levels. Three patients reported adverse events: musculoskeletal pain (n=2) and injection-site symptoms (n=1). CONCLUSIONS: Lanreotide Autogel is effective and well tolerated in patients with acromegaly. This study in a small group of patients with well-controlled acromegaly suggests that the majority of patients switched from 20 mg LAR to 90 mg Autogel will have equivalent or better disease control.

This article has been cited by other articles:

				R. D. Murray and S. Melmed A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2957 - 2968. [Abstract] [Full Text] [PDF]

				A. Colao, J. Marek, M. I. Goth, P. Caron, J. M. Kuhn, F. M. Minuto, and N. J. Weissman No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2243 - 2248. [Abstract] [Full Text] [PDF]

				B. Astruc, P. Marbach, H. Bouterfa, C. Denot, M. Safari, A. Vitaliti, and M. Sheppard Long-Acting Octreotide and Prolonged-Release Lanreotide Formulations Have Different Pharmacokinetic Profiles J. Clin. Pharmacol., July 1, 2005; 45(7): 836 - 844. [Abstract] [Full Text] [PDF]

				J. Wass Debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogues Eur. J. Endocrinol., May 1, 2005; 152(5): 693 - 694. [Full Text] [PDF]